Immunocore Holdings (IMCR) Capital Expenditures (2021 - 2026)

Immunocore Holdings (IMCR) has reported Capital Expenditures for 6 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures rose 497.65% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 15.51% YoY) and the FY2025 annual result came in at $4.3 million, down 16.1% from the prior year.
• Capital Expenditures retreated to $1.8 million in Q1 2026 per IMCR's latest filing, from $2.9 million in the prior quarter.
• Over the last five years, Capital Expenditures for IMCR reached as high as $3.6 million in Q4 2024 and fell as low as $212000.0 in Q3 2023.
• A 5-year average of $1.2 million and a median of $817000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures slumped 85.67% — and 2026, when it jumped 497.65%.
• Year by year, Capital Expenditures stood at $1.1 million in 2022, then retreated by 24.12% to $817000.0 in 2023, then surged by 338.68% to $3.6 million in 2024, then decreased by 19.64% to $2.9 million in 2025, then plunged by 38.16% to $1.8 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $1.8 million, $2.9 million, and $748000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.